-2%
Doxiflo is indicated for the treatment and management of:
- Bronchial Asthma
- Bronchospasm
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary disorders with spastic bronchial components
Doxophylline is a novel bronchodilator structurally related to theophylline but distinguished by the presence of a dioxolane group at position 7.
It acts by selectively inhibiting phosphodiesterase-4 (PDE-4), resulting in bronchial smooth muscle relaxation and improved airflow.
Unlike theophylline, Doxophylline has a lower affinity for adenosine A1 and A2 receptors, which contributes to its better safety and tolerability.
Additionally, it inhibits platelet-activating factor (PAF) and leukotriene synthesis, offering anti-inflammatory benefits.